Name: Recombinant Anti-CD20 x Anti-CD47 sdAb Bispecific Antibody (IgG-sdAb)
SKU: IGVHH-010
Rating: 5 (1 reviews)

Recombinant Anti-CD20 x Anti-CD47 Bispecific Antibody (IgG-sdAb) is designed to be expressed as a LC and an extended HC with a sdAb linked to the C terminus. It is a symmetric bispecific and tetravalent molecule, bivalent for each antigen specificity, 2+2 antigen-binding valency. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Lymphoma therapy. As required, the sdAb can also be fused to the C terminus of the LC.

Datasheet INQUIRY

Specifications

Targets

CD20 & CD47

Type

IgG-sdAb

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma

Host Animal 1

Mouse

Host Animal 2

llama

Targets

Target 1

CD20

Gene ID

931

UniProt ID

A0A024R507

Alternative Names

MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1

Target 2

CD47

Gene ID

961

UniProt ID

Q08722

Alternative Names

CD47; CD47 molecule; IAP; OA3; MER6; leukocyte surface antigen CD47; CD47 glycoprotein; Rh-related antigen; integrin associated protein; integrin-associated protein; integrin-associated signal transducer; antigenic surface determinant protein OA3; antigen identified by monoclonal antibody 1D8; CD47 antigen (Rh-related antigen, integrin-associated signal transducer)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD20 x Anti-CD47 sdAb Bispecific Antibody (IgG-sdAb) (IGVHH-010). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD20 x Anti-CD47 sdAb Bispecific Antibody (IgG-sdAb) (CAT#: IGVHH-010)

Specifications

Targets

Customer Reviews and Q&As